Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI135585 XX Administered as Tablet and as Solution in Healthy Volunteers
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo to BI 135585
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT01146886
- Locations
- 🇩🇪
1283.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7
- Registration Number
- NCT01145885
- Locations
- 🇭🇺
1230.23.36001 Boehringer Ingelheim Investigational Site, Budapest, Hungary
Drug Use Survey of RESPIMAT in Patients With COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2010-06-16
- Last Posted Date
- 2014-03-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 361
- Registration Number
- NCT01145053
To Investigate Safety, Tolerability, and Pharmacokinetics of Treatment With BI 660848 Rising Single Doses (From 2 mg to 600 mg) Administered as Oral Drinking Solution (Powder in Bottle).
- First Posted Date
- 2010-06-16
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT01145014
- Locations
- 🇩🇪
1284.1.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA
- Conditions
- Venous Thromboembolism
- First Posted Date
- 2010-06-08
- Last Posted Date
- 2014-01-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1676
- Registration Number
- NCT01139658
- Locations
- 🇫🇷
Boehringer Ingelheim Investigational Site 19, Lyon, France
🇫🇷Boehringer Ingelheim Investigational Site 30, Angers, France
🇫🇷Boehringer Ingelheim Investigational Site 40, Beauvais, France
A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 174
- Registration Number
- NCT01136408
- Locations
- 🇯🇵
1160.49.014 Boehringer Ingelheim Investigational Site, Suita, Osaka, Japan
🇯🇵1160.49.027 Boehringer Ingelheim Investigational Site, Iizuka,Fukuoka, Japan
🇯🇵1160.49.013 Boehringer Ingelheim Investigational Site, Kyoto, Kyoto, Japan
Safety and PK Study of BIBF 1120 in Japanese Patients With IPF
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2015-01-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT01136174
- Locations
- 🇯🇵
1199.31.002 Boehringer Ingelheim Investigational Site, Bunkyo-ku,Tokyo, Japan
🇯🇵1199.31.004 Boehringer Ingelheim Investigational Site, Hamamatsu, Shizuoka, Japan
🇯🇵1199.31.006 Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan
TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch
- Conditions
- Hypertension
- Interventions
- Drug: telmisartan/amlodipine
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2014-01-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 502
- Registration Number
- NCT01134393
- Locations
- 🇮🇹
1235.33.39009 Boehringer Ingelheim Investigational Site, Arezzo, Italy
🇮🇹1235.33.39002 Boehringer Ingelheim Investigational Site, Bologna, Italy
🇩🇪1235.33.49010 Boehringer Ingelheim Investigational Site, Berlin, Germany
Non-interventional Observational Study With Viramune® in HIV to Evaluate Gender Specific Data
- Conditions
- HIV Infections
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 265
- Registration Number
- NCT01134939
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site 21, Leipzig, Germany
🇩🇪Boehringer Ingelheim Investigational Site 10, Berlin, Germany
🇩🇪Boehringer Ingelheim Investigational Site 11, Berlin, Germany
to Evaluate Effect of Multi Doses Flibans 100 mg Film-c Tablets on Single Dose PK of Digoxin 0.5 mg, Healthy Volunteers
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT01134965
- Locations
- 🇩🇪
511.158.1 Boehringer Ingelheim Investigational Site, Biberach, Germany